Protocol #: 17-021
Status
Recruiting
Description
This research study is studying a combination of drugs with radiation therapy as a possible treatment for Microsatellite Stable Colorectal Cancer, Pancreatic Cancer, or MSI High Colorectal Cancer. The interventions involved in this study are: - Nivolumab - Ipilimumab - Radiation Therapy
Condition
Microsatellite Stable Colorectal Cancer
Pancreatic Cancer
MSI High Colorectal Cancer
Interventions
Nivolumab
Ipilimumab
Radiation Therapy
Phase
Phase 2
Study Type
Interventional
Further Study Details
Primary Outcome:
Disease Control Rate
Secondary Outcome:
Median Progression free Survival
Median Overall Survival
Estimated Enrollment
80
Study Start Date
May 10, 2017
Eligibility
Gender: All
Minimum Age: 18 Years
Maximum Age: N/A
Health Volunteers: No
Criteria
Massachusetts General Hospital
Information Provided By
Massachusetts General Hospital
Official Title
Nivolumab and Ipilimumab and Radiation Therapy in Microsatellite Stable (MSS) and Microsatellite Instability (MSI) High Colorectal and Pancreatic Cancer
Clinicaltrials.gov Identifier
NCT03104439

 

 

Source: Clinicaltrials.gov. Through our founding membership in the Dana-Farber/Harvard Cancer Center, an NCI-designated Comprehensive Cancer Center, these clinical trials are conducted at the Massachusetts General Hospital Cancer Center and may be available at other partner institutions.

Back to Top